Caricamento...
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...
Salvato in:
| Pubblicato in: | Indian J Endocrinol Metab |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medknow Publications & Media Pvt Ltd
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/ https://ncbi.nlm.nih.gov/pubmed/27042424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|